Objective: Macrophage activation syndrome (MAS) is a life-threatening complication of systemic juvenile idiopathic arthritis (sJIA) characterised by a vicious cycle of immune amplification that can culminate in overwhelming inflammation and multiorgan failure. The clinical features of MAS overlap with those of active sJIA, complicating early diagnosis and treatment. We evaluated adenosine deaminase 2 (ADA2), a protein of unknown function released principally by monocytes and macrophages, as a novel biomarker of MAS.
Methods: We established age-based normal ranges of peripheral blood ADA2 activity in 324 healthy children and adults. We compared these ranges with 173 children with inflammatory and immune-mediated diseases, including systemic and non-systemic JIA, Kawasaki disease, paediatric systemic lupus erythematosus and juvenile dermatomyositis.
Results: ADA2 elevation beyond the upper limit of normal in children was largely restricted to sJIA with concomitant MAS, a finding confirmed in a validation cohort of sJIA patients with inactive disease, active sJIA without MAS or sJIA with MAS. ADA2 activity strongly correlated with MAS biomarkers including ferritin, interleukin (IL)-18 and the interferon (IFN)-γ-inducible chemokine CXCL9 but displayed minimal association with the inflammatory markers C reactive protein and erythrocyte sedimentation rate. Correspondingly, ADA2 paralleled disease activity based on serial measurements in patients with recurrent MAS episodes. IL-18 and IFN-γ elicited ADA2 production by peripheral blood mononuclear cells, and ADA2 was abundant in MAS haemophagocytes.
Conclusions: These findings collectively identify the utility of plasma ADA2 activity as a biomarker of MAS and lend further support to a pivotal role of macrophage activation in this condition.
Keywords: adenosine deaminase 2; biomarker; macrophage activation syndrome; systemic juvenile idiopathic arthritis.
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Follistatin-like protein 1 and the ferritin/erythrocyte sedimentation rate ratio are potential biomarkers for dysregulated gene expression and macrophage activation syndrome in systemic juvenile idiopathic arthritis.J Rheumatol. 2013 Jul;40(7):1191-9. doi: 10.3899/jrheum.121131. Epub 2013 May 15. J Rheumatol. 2013. PMID: 23678162 Free PMC article.
Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ.Rheumatology (Oxford). 2015 Aug;54(8):1507-17. doi: 10.1093/rheumatology/keu524. Epub 2015 Mar 12. Rheumatology (Oxford). 2015. PMID: 25767156
IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome.Rheumatology (Oxford). 2020 Feb 1;59(2):361-366. doi: 10.1093/rheumatology/kez282. Rheumatology (Oxford). 2020. PMID: 31326996
Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis.Pediatr Rheumatol Online J. 2015 Dec 3;13:55. doi: 10.1186/s12969-015-0055-3. Pediatr Rheumatol Online J. 2015. PMID: 26634252 Free PMC article. Review.
Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management.Paediatr Drugs. 2020 Feb;22(1):29-44. doi: 10.1007/s40272-019-00367-1. Paediatr Drugs. 2020. PMID: 31732958 Review.